Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
UNICANCER
UNICANCER
Hospices Civils de Lyon
Abramson Cancer Center at Penn Medicine
Institut Català d'Oncologia
H. Lee Moffitt Cancer Center and Research Institute
Duke University
Sixth Affiliated Hospital, Sun Yat-sen University
Duke University
Pancreatic Cancer Research Team
H. Lee Moffitt Cancer Center and Research Institute